Portal Innovations LLC
07/14/2026 | Press release | Archived content
Portal portfolio company, Syntax Bio expands its Series A to $14.4 million
Uncategorized
07.14.26Portal portfolio company, Syntax Bio expands its Series A to $14.4 million
Share
Congratulations to our Chicago-based portfolio company, Syntax Bio, on expanding its Series A to $14.4 million and surpassing $25 million in total funding. Syntax is advancing the frontiers of regenerative medicine through its Cellgorithm™ platform and pioneering pancreatic beta cell therapies for type 1 diabetes.
Read their full release!
Portal Innovations LLC published this content on July 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 23, 2026 at 04:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]